Ref ID: 19363
Author:
G. L. Johnson, M. Shannon, C. R. Thornton, S. G. Agrawal
and S. A. Bustin
Author address:
Queen Mary University of London, London, United Kingdom;
Life Technologies Corporation, Foster City, USA; School of
Biosciences, University of Exeter, Exeter, United Kingdom and
Postgraduate Medical Institute, Anglia Ruskin University,
Chelmsford
Full conference title:
6th Trends in Medical Mycology 2013
Date: 11 October 2014
Abstract:
Objective The Proximity Ligation Assay (PLA) uses real-time PCR
(qPCR) to detect the binding of oligonucleotide-labelled antibodies to
their antigens. Our aim was to demonstrate the utility of this method
as a diagnostic assay for the early detection of fungal infections.
This first assay targets invasive aspergillosis by detecting Aspergillus-
specific proteins secreted only during active fungal growth.
Methods Generation of PLA-probes:
1. Polyclonal antibodies (pAb) were raised against an Aspergillus-specific
glycoprotein antigen that is secreted constitutively at the hyphal apex.
2. pAbs were biotinylated, and tested to ensure efficient biotinyla-
tion in a “œforced proximity test”.
3. Biotinylated pAbs were split into 2 pools and streptavidin-linked
oligonucleotides A or B were added to one or other of the pAb pools.
This generates probe pools attached to different DNA oligonucleo-
tides, one with a free 3’- (A), the other a free 5’-end (B).
The PLA assay:
4. Both PLA probes were combined and incubated with dilutions
of purified glycoprotein antigen or Aspergillus lysate. The reaction
mixture also contained a third oligonucleotide that is complementary
to the end of oligonucleotide A and the beginning of oligonucleotide
B. If antigen is present, it connects the two oligonucleotides, allowing
a ligase to seal the free ends. Control reactions contained antibodies
but no antigen.
5. Primers complementary to oligonucleotides A and B were used
to amplify ligated amplification products, which were detected with a
hydrolysis probe.
Analysis:
6. Serial dilutions of purified glycoprotein antigen in phosphate-
buffered saline (PBS) were used to determine the quantitative poten-
tial of this method. The Mann-Whitney U-test was used to calculate
the statistical significance between the quantification cycles (Cq) of
samples with and without A. fumigatus lysate.
Results The amplification plot of the forced proximity test is shown
in Figure 1 and indicated a 2,100-fold difference between the bioti-
nylated antibody (blue replicates) and the negative control (pink rep-
licates), which is significantly above the 360-fold quality control
threshold. Figure 2 shows increasing Cqs with serial 10-fold dilution
of purified glycoprotein antigen in PBS (A to D), with an 8-fold differ-
ence between the highest dilution (D) and the antigen-negative sam-
ple (Negative C). Serial dilutions of Aspergillus lysate were tested and
showed a statistically significant difference between Aspergillus-posi-
tive and Aspergillus-negative samples (n = 14, median positive Cq:
26.15, median negative Cq: 28.19; P < 0.05). Unlike standard qPCR,
the negative control in a PLA generates aCq due to ligation of PLA
probes being brought into proximity by chance.
Conclusion This report describes the first ever use of PLA to detect
proteins secreted by actively growing fungi. Results demonstrate the
successful biotinylation and oligonucleotide attachment of the pAb,
the ability of the PLA to detect its target antigen and a statistically
significant difference between the Cq of an Aspergillus lysate contain-
ing target antigen and an antigen-negative sample. Assay optimisa-
tion will increase the Cq of the negative control to a value of >30.
Normalisation against chromosomal DNA present in the sample
should permit translation of qPCR quantification cycles into a quanti-
tative assay that determines proliferating fungal load within a patient
sample.
Figure 1 Amplification plot of the pAb Forced Proximity Probe. The
blue lines are the biotinylated antibody. The pink lines are the nega-
tive control.
Abstract Number: o2.6
Conference Year: 2013
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a